Apogee enters antibody discovery agreement with Paragon Therapeutics

Apogee Therapeutics signed an Antibody Discovery Agreement with Paragon Therapeutics effective June 17, 2026, for discovery and development of monospecific antibody candidates. The agreement includes a concurrent License Agreement enabling Apogee to further develop, manufacture and commercialize resulting antibodies.